Holen Sie sich die Stockscreener-App
18.56
5.31%
-1.04
Schlusskurs vom Vortag:
$19.60
Offen:
$19.39
24-Stunden-Volumen:
469.54K
Relative Volume:
0.66
Marktkapitalisierung:
$1.28B
Einnahmen:
Nettoeinkommen (Verlust:
$-131.11M
KGV:
-8.5353
EPS:
-2.1745
Netto-Cashflow:
$-102.47M
1W Leistung:
-8.30%
1M Leistung:
-15.75%
6M Leistung:
-47.89%
1J Leistung:
+29.25%
1-Tages-Spanne:
$18.54
$19.60
1-Wochen-Bereich:
$18.54
$20.79
52-Wochen-Spanne:
$13.35
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
18.56 | 1.28B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - GlobeNewswire Inc.
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance UK
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance Australia
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biotech fund group reports stake in Tyra Biosciences (NASDAQ: TYRA) — here’s how much of the company it holds - Stock Titan
Tyra Biosciences (Nasdaq:TYRA)Stock Analysis - simplywall.st
Press Releases about Tyra Biosciences, Inc.Common Stock (Nasdaq:TYRA) - FinancialContent
Tyra Biosciences (NASDAQ: TYRA) CEO lifts stake to 1,438,495 shares - Stock Titan
Stock grant lifts Tyra Biosciences (NASDAQ: TYRA) finance VP stake to 11,258 shares - Stock Titan
CFO adds shares in Tyra Biosciences (TYRA) via plan - Stock Titan
Tyra Biosciences (TYRA) investor uses capped warrants to reach 19.99% stake - Stock Titan
RA Capital buys $0.001-share warrants in Tyra Biosciences (TYRA) - Stock Titan
Investor group reports over 5% stake in Tyra Biosciences (TYRA) - Stock Titan
Tyra Announces $400M Pricing of Common Stock and Pre-Funded Warrants - TradingView
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday - Benzinga
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - PR Newswire
A biotech expects to raise about $400 million for drug development. Tyra priced the stock sale. - Stock Titan
Update: Tyra Bioscience Shares Rise After Pricing $400 Million Offering - Yahoo Finance
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Tyra Bioscience Prices $400 Million Offering of Shares and Warrants - Yahoo Finance
Tyra Biosciences (TYRA) director adds shares in open-market buy - Stock Titan
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC - CancerNetwork
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data - Investing.com
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBCSlideshow (NASDAQ:TYRA) 2026-09-10 - Seeking Alpha
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $30 to $59 - Moomoo
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30 - moomoo.com
Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push - Investing.com Canada
Tyra disappoints investors with bladder cancer data - BioPharma Dive
TYRA: Oral FGFR3 inhibitor shows robust efficacy and safety, advancing to phase III for MIBC - TradingView
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
Balversa reversa? Tyra’s bladder cancer drug hits in phase II - BioWorld News
Tyra Biosciences reports 79% response rate for bladder cancer drug dabogratinib - Minichart
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
TYRA: Oral dabogratinib at 60 mg shows strong efficacy and safety, advancing to phase III in NMIBC - TradingView
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Australia
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - Yahoo Finance
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results - investing.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com India
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Nigeria
Tyra drops after mid-stage trial data for lead asset in bladder cancer - TradingView
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tyra Biosciences Inc-Aktie (TYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| NEXTECH VI ONCOLOGY SCSP | Shareholder |
Jun 26 '26 |
Proposed Sale |
30.94 |
308,379 |
9,541,246 |
0 |
| NEXTECH VI ONCOLOGY SCSP | Shareholder |
Jun 01 '26 |
Proposed Sale |
33.41 |
300,000 |
10,023,000 |
0 |
| Daniel Bensen | Officer |
May 12 '26 |
Proposed Sale |
34.25 |
8,000 |
274,000 |
0 |
| Daniel Bensen | Officer |
Apr 13 '26 |
Proposed Sale |
35.62 |
8,000 |
285,000 |
0 |
| GILLA KAPLAN | Director |
Mar 26 '26 |
Proposed Sale |
37.75 |
53,172 |
2,007,153 |
0 |
| KAPLAN GILLA | Director |
Mar 25 '26 |
Sale |
36.97 |
14,295 |
528,506 |
28,231 |
| KAPLAN GILLA | Director |
Mar 25 '26 |
Option Exercise |
2.25 |
14,295 |
32,164 |
42,526 |
| GILLA KAPLAN | Director |
Mar 25 '26 |
Proposed Sale |
36.97 |
14,295 |
528,506 |
0 |
| Daniel Bensen | Officer |
Mar 12 '26 |
Proposed Sale |
35.38 |
8,000 |
283,000 |
0 |
| Bensen Daniel | Chief Discovery Officer |
Feb 12 '26 |
Sale |
32.87 |
8,000 |
262,965 |
146,981 |
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):